nach oben

Erschienen in:

01.07.2012 | Original Paper

CSF biomarkers cutoffs: the importance of coincident neuropathological diseases

verfasst von: Jon B. Toledo, Johannes Brettschneider, Murray Grossman, Steven E. Arnold, William T. Hu, Sharon X. Xie, Virginia M.-Y. Lee, Leslie M. Shaw, John Q. Trojanowski

Erschienen in: Acta Neuropathologica | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Abstract

The effects of applying clinical versus neuropathological diagnosis and the inclusion of cases with coincident neuropathological diagnoses have not been assessed specifically when studying cerebrospinal fluid (CSF) biomarker classification cutoffs for patients with neurodegenerative diseases that cause dementia. Thus, 142 neuropathologically diagnosed neurodegenerative dementia patients [71 Alzheimer’s disease (AD), 29 frontotemporal lobar degeneration (FTLD), 3 amyotrophic lateral sclerosis, 7 dementia with Lewy bodies, 32 of which cases also had coincident diagnoses] were studied. 96 % had enzyme-linked immunosorbant assay (ELISA) CSF data and 77 % had Luminex CSF data, with 43 and 46 controls for comparison, respectively. Aβ₄₂, total, and phosphorylated tau₁₈₁ were measured. Clinical and neuropathological diagnoses showed an 81.4 % overall agreement. Both assays showed high sensitivity and specificity to classify AD subjects against FTLD subjects and controls, and moderate sensitivity and specificity for classifying FTLD subjects against controls. However, among the cases with neuropathological diagnoses of AD plus another pathology (26.8 % of the sample), 69.4 % (ELISA) and 96.4 % (Luminex) were classified as AD according to their biomarker profiles. Use of clinical diagnosis instead of neuropathological diagnosis led to a 14–17 % underestimation of the biomarker accuracy. These results show that while CSF Aβ and tau assays are useful for diagnosis of AD and neurodegenerative diseases even at MCI stages, CSF diagnostic analyte panels that establish a positive diagnosis of Lewy body disease and FTLD are also needed, and must be established based on neuropathological rather than clinical diagnoses.

Nur mit Berechtigung zugänglich

Acosta-Baena N, Sepulveda-Falla D, Lopera-Gomez CM et al (2011) Pre-dementia clinical stages in presenilin 1 E280A familial early-onset Alzheimer’s disease: a retrospective cohort study. Lancet neurology 10(3):213–220PubMedCrossRef

Albert MS, DeKosky ST, Dickson D et al (2011) The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 7(3):270–279PubMedCrossRef

Alzheimer A (1907) Über eine eigenartige Erkrankung der Hirnrinde. Allgemeine Zeitschrift für Psychiatrie und psychisch-gerichtliche Medizin 64 Band, Verlag von Georg Reimer

Bian H, Van Swieten JC, Leight S et al (2008) CSF biomarkers in frontotemporal lobar degeneration with known pathology. Neurology 70(19 Pt 2):1827–1835PubMed

Blennow K, Hampel H, Weiner M, Zetterberg H (2010) Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 6(3):131–144PubMedCrossRef

Braak H, Braak E (1991) Neuropathological staging of Alzheimer-related changes. Acta Neuropathol 82(4):239–259PubMedCrossRef

Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K (2006) Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol 112(4):389–404PubMedCrossRef

Buchhave P, Minthon L, Zetterberg H et al (2012) Cerebrospinal fluid levels of beta-Amyloid 1-42, but not of Tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry 69(1):98–106PubMedCrossRef

Clark CM, Xie S, Chittams J et al (2003) Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? Arch Neurol 60(12):1696–1702PubMedCrossRef

10.

De Meyer G, Shapiro F, Vanderstichele H et al (2010) Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. Arch Neurol 67(8):949–956PubMedCrossRef

11.

Dubois B, Feldman HH, Jacova C et al (2007) Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 6(8):734–746PubMedCrossRef

12.

Dubois B, Feldman HH, Jacova C et al (2010) Revising the definition of Alzheimer’s disease: a new lexicon. Lancet Neurol 9(11):1118–1127PubMedCrossRef

13.

Echavarri C, Caballero MC, Aramendia A, Garcia-Bragado F, Tunon T (2011) Multiprotein deposits in neurodegenerative disorders: our experience in the tissue brain bank of Navarra. Anat Rec (Hoboken) 294(7):1191–1197CrossRef

14.

Emre M, Aarsland D, Brown R, et al (2007) Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Mov Disord 22(12):1689–1707 (quiz 1837)

15.

Engelborghs S, De Vreese K, Van de Casteele T et al (2008) Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia. Neurobiol Aging 29(8):1143–1159PubMedCrossRef

16.

Frisoni GB, Fox NC, Jack CR Jr, Scheltens P, Thompson PM (2010) The clinical use of structural MRI in Alzheimer disease. Nat Rev Neurol 6(2):67–77PubMedCrossRef

17.

Gelb DJ, Oliver E, Gilman S (1999) Diagnostic criteria for Parkinson disease. Arch Neurol 56(1):33–39PubMedCrossRef

18.

Geser F, Martinez-Lage M, Robinson J et al (2009) Clinical and pathological continuum of multisystem TDP-43 proteinopathies. Arch Neurol 66(2):180–189PubMedCrossRef

19.

Geser F, Robinson JL, Malunda JA et al (2010) Pathological 43-kDa transactivation response DNA-binding protein in older adults with and without severe mental illness. Arch Neurol 67(10):1238–1250PubMedCrossRef

20.

Gorno-Tempini ML, Hillis AE, Weintraub S et al (2011) Classification of primary progressive aphasia and its variants. Neurology 76(11):1006–1014PubMedCrossRef

21.

Grossman M, Farmer J, Leight S et al (2005) Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer’s disease. Ann Neurol 57(5):721–729PubMedCrossRef

22.

Grossman M, Libon DJ, Forman MS et al (2007) Distinct antemortem profiles in patients with pathologically defined frontotemporal dementia. Arch Neurol 64(11):1601–1609PubMedCrossRef

23.

Hothorn T, Hornik K, van de Wiel MA, Zeileis A (2006) A Lego system for conditional inference. Am Stat 60(3):257–263CrossRef

24.

Hu W, Chen-Plotkin A, Arnold S et al (2010) Biomarker discovery for Alzheimer’s disease, frontotemporal lobar degeneration, and Parkinson’s disease. Acta Neuropathol 120(3):385–399PubMedCrossRef

25.

Hu WT, Trojanowski JQ and Shaw LM (2011) Biomarkers in frontotemporal lobar degenerations—progress and challenges. Prog Neurobiol (in press, corrected proof)

26.

Hyman BT, Trojanowski JQ (1997) Consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer disease. J Neuropathol Exp Neurol 56(10):1095–1097PubMedCrossRef

27.

Ikonomovic MD, Klunk WE, Abrahamson EE et al (2008) Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer’s disease. Brain 131(6):1630–1645PubMedCrossRef

28.

Jack CR Jr, Knopman DS, Jagust WJ et al (2010) Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet Neurol 9(1):119–128PubMedCrossRef

29.

Jack CR Jr, Vemuri P, Wiste HJ et al (2011) Evidence for ordering of Alzheimer disease biomarkers. Arch Neurol 68(12):1526–1535PubMedCrossRef

30.

Jellinger KA (2008) Neuropathological aspects of Alzheimer disease, Parkinson disease and frontotemporal dementia. Neurodegener Dis 5(3–4):118–121PubMedCrossRef

31.

Jellinger KA, Attems J (2010) Prevalence of dementia disorders in the oldest-old: an autopsy study. Acta Neuropathol 119(4):421–433PubMedCrossRef

32.

Khachaturian ZS (1985) Diagnosis of Alzheimer’s disease. Arch Neurol 42(11):1097–1105PubMedCrossRef

33.

Kuhn M (2008) Building Predictive Models in R Using the caret. J Stat Softw 28

34.

Ling H, O’Sullivan SS, Holton JL et al (2010) Does corticobasal degeneration exist? A clinicopathological re-evaluation. Brain 133(7):2045–2057PubMedCrossRef

35.

Lo RY, Hubbard AE, Shaw LM et al (2011) Longitudinal change of biomarkers in cognitive decline. Arch Neurol 68(10):1257–1266

36.

Mackenzie I, Neumann M, Bigio E et al (2010) Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathol 119(1):1–4PubMedCrossRef

37.

McKeith IG, Dickson DW, Lowe J et al (2005) Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 65(12):1863–1872PubMedCrossRef

38.

McKhann GM, Knopman DS, Chertkow H et al (2011) The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 7(3):263–269PubMedCrossRef

39.

Mirra SS, Heyman A, McKeel D et al (1991) The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer’s disease. Neurology 41(4):479–486PubMedCrossRef

40.

Mollenhauer B, Esselmann H, Trenkwalder C et al (2011) CSF amyloid-beta peptides in neuropathologically diagnosed dementia with Lewy bodies and Alzheimer’s disease. J Alzheimers Dis 24(2):383–391PubMed

41.

Mollenhauer B, Locascio JJ, Schulz-Schaeffer W et al (2011) alpha-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol 10(3):230–240PubMedCrossRef

42.

Neumann M, Sampathu DM, Kwong LK et al (2006) Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314(5796):130–133PubMedCrossRef

43.

Neumann M, Kwong LK, Lee EB et al (2009) Phosphorylation of S409/410 of TDP-43 is a consistent feature in all sporadic and familial forms of TDP-43 proteinopathies. Acta Neuropathol 117(2):137–149PubMedCrossRef

44.

Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS) (2001) Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Lancet 357(9251):169s–175s

45.

Nordberg A, Rinne JO, Kadir A, Langstrom B (2010) The use of PET in Alzheimer disease. Nat Rev Neurol 6(2):78–87PubMedCrossRef

46.

Olsson A, Vanderstichele H, Andreasen N et al (2005) Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. Clin Chem 51(2):336–345PubMedCrossRef

47.

Parnetti L, Chiasserini D, Bellomo G et al (2011) Cerebrospinal fluid tau/α-synuclein ratio in Parkinson’s disease and degenerative dementias. Mov Disord 26(8):1428–1435PubMedCrossRef

48.

Prvulovic D, Hampel H (2011) Amyloid beta (Abeta) and phospho-tau (p-tau) as diagnostic biomarkers in Alzheimer’s disease. Clin Chem Lab Med 49(3):367–374PubMedCrossRef

49.

R Development Core Team (2011) R: a language and environment for statistical computing. In: R Foundation for statistical computing. Vienna, Austria

50.

Rascovsky K, Hodges JR, Knopman D et al (2011) Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 134(9):2456–2477

51.

Robin X, Turck N, Hainard A et al (2011) pROC: an open-source package for R and S + to analyze and compare ROC curves. BMC Bioinformatics 12:77PubMedCrossRef

52.

Schneider JA, Arvanitakis Z, Bang W, Bennett DA (2007) Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology 69(24):2197–2204PubMedCrossRef

53.

Schneider JA, Arvanitakis Z, Leurgans SE, Bennett DA (2009) The neuropathology of probable Alzheimer disease and mild cognitive impairment. Ann Neurol 66(2):200–208PubMedCrossRef

54.

Schoonenboom NS, Reesink FE, Verwey NA et al (2012) Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort. Neurology 78(1):47–54PubMedCrossRef

55.

Shaw LM, Korecka M, Clark CM, Lee VMY, Trojanowski JQ (2007) Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics. Nat Rev Drug Discov 6(4):295–303PubMedCrossRef

56.

Shaw LM, Vanderstichele H, Knapik-Czajka M et al (2009) Cerebrospinal fluid biomarker signature in Alzheimer’s disease neuroimaging initiative subjects. Annals of Neurology 65(4):403–413PubMedCrossRef

57.

Shi M, Bradner J, Hancock AM et al (2011) Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol 69(3):570–580PubMedCrossRef

58.

Sinha N, Firbank M, O’Brien JT (2011) Biomarkers in dementia with Lewy bodies: a review. Int J Geriatr Psychiatry. doi:10.1002/gps.2749

59.

Tapiola T, Alafuzoff I, Herukka SK et al (2009) Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol 66(3):382–389PubMedCrossRef

60.

Toledo JB, Vanderstichele H, Figurski M et al (2011) Factors affecting Abeta plasma levels and their utility as biomarkers in ADNI. Acta Neuropathol 122(4):401–413PubMedCrossRef

61.

Urwin H, Josephs KA, Rohrer JD et al (2011) FUS pathology defines the majority of tau- and TDP-43-negative frontotemporal lobar degeneration. Acta Neuropathol 120(1):33–41CrossRef

62.

Uryu K, Nakashima-Yasuda H, Forman MS et al (2008) Concomitant TAR-DNA-binding protein 43 pathology is present in Alzheimer disease and corticobasal degeneration but not in other tauopathies. J Neuropathol Exp Neurol 67(6):555–564PubMedCrossRef

63.

van Harten AC, Kester MI, Visser PJ et al (2011) Tau and p-tau as CSF biomarkers in dementia: a meta-analysis. Clin Chem Lab Med 49(3):353–366PubMedCrossRef

64.

Vemuri P, Wiste HJ, Weigand SD et al (2010) Serial MRI and CSF biomarkers in normal aging, MCI, and AD. Neurology 75(2):143–151PubMedCrossRef

65.

Venables WN and Ripley BD (2002). In: Chambers WEJ, Hardle W, Sheather S, Tierney L (eds) Modern applied statistics with S. Springer Verlag, New York

66.

Winton MJ, Lee EB, Sun E et al (2011) Intraneuronal APP, not free Abeta peptides in 3xTg-AD mice: implications for tau versus Abeta-mediated Alzheimer neurodegeneration. J Neurosci 31(21):7691–7699PubMedCrossRef

67.

Xie SX, Ewbank DC, Chittams J et al (2009) Rate of decline in Alzheimer disease measured by a Dementia Severity Rating Scale. Alzheimer Dis Assoc Disord 23(3):268–274PubMedCrossRef

68.

Xie SX, Libon DJ, Wang X et al (2010) Longitudinal patterns of semantic and episodic memory in frontotemporal lobar degeneration and Alzheimer’s disease. J Int Neuropsychol Soc 16(2):278–286PubMedCrossRef

69.

Xie SX, Baek Y, Grossman M et al (2011) Building an integrated neurodegenerative disease database at an academic health center. Alzheimers Dement 7(4):e84–e93PubMedCrossRef

Titel: CSF biomarkers cutoffs: the importance of coincident neuropathological diseases
verfasst von: Jon B. Toledo
Johannes Brettschneider
Murray Grossman
Steven E. Arnold
William T. Hu
Sharon X. Xie
Virginia M.-Y. Lee
Leslie M. Shaw
John Q. Trojanowski
Publikationsdatum: 01.07.2012
Verlag: Springer-Verlag
Erschienen in: Acta Neuropathologica / Ausgabe 1/2012
Print ISSN: 0001-6322
Elektronische ISSN: 1432-0533
DOI: https://doi.org/10.1007/s00401-012-0983-7

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2012

Ubiquilin immunoreactivity in cytoplasmic and nuclear inclusions in synucleinopathies, polyglutamine diseases and intranuclear inclusion body disease

Erratum to: Decreased pyramidal neuron size in Brodmann areas 44 and 45 in patients with autism

Matrix metalloproteinase-12 deficiency ameliorates the clinical course and demyelination in Theiler’s murine encephalomyelitis

Brain pathology of spinocerebellar ataxias

Mycoplasmal panencephalitis: a neuropathologic documentation